On May 3, 2017, a federal jury in Louisiana found against a Xarelto plaintiff who claimed that the defendants, Johnson & Johnson (“J & J”) and Bayer AG, had inadequately warned him regarding the internal bleeding risk associated with Xarelto, a blood-thinning medication that has no antidote and may lead to irreversible, uncontrollable internal bleeding in emergencies.
The 75-year-old plaintiff alleged that he was prescribed Xarelto in 2014 to treat a heart condition and that he subsequently suffered gastrointestinal bleeding that required blood transfusions and hospitalization. The plaintiff alleged in his Xarelto lawsuit that Xarelto is an unreasonably dangerous drug.
The plaintiff had also alleged that Xarelto was defectively designed and that the defendants had mislead him and his physicians regarding the health risks associated with Xarelto.
There are more than 18,000 Xarelto lawsuits pending against J & J’s subsidiary, Janssen Pharmaceuticals, Inc. (“Janssen”), and Bayer AG, which co-developed Xarelto, which is a very lucrative product for both companies. The Xarelto claims include the alleged failure to adequately warn doctors and patients regarding the internal bleeding risks of Xarelto and that there is no antidote for Xarelto, unlike for the older blood thinners such as Coumadin (warfarin). Some Xarelto plaintiffs allege that they should have been warned that they should be tested for their internal bleeding risk before being prescribed Xarelto.
The Xarelto defendants contend that Xarelto is not defectively designed, that adequate warnings are included with the blood thinning medication, that Xarelto provides benefits over older blood thinning medications, such as eliminating the need for routine blood testing required when taking the older blood thinners, and that Xarelto is a safe and effective medication, as determined by the FDA.
What Is Xarelto?
Janssen states on its website that Xarelto is “a prescription medicine used to reduce the risk of stroke and blood clots in people with atrial fibrillation, not caused by a heart valve problem. For patients currently well managed on warfarin, there is limited information on how Xarelto and warfarin compare in reducing the risk of stroke. Xarelto is also a prescription medicine used to treat deep vein thrombosis and pulmonary embolism, and to help reduce the risk of these conditions occurring again. Xarelto is also a prescription medicine used to reduce the risk of forming a blood clot in the legs and lungs of people who have just had knee or hip replacement surgery.”
On April 28, 2017, Bayer AG announced in a press release issued outside of the United States that it and Janssen had submitted “a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to update the prescribing information for the oral Factor Xa inhibitor rivaroxaband (Xarelto), to include a 10 mg once-daily dose for reducing the risk of recurrent venous thromboembolism (VTE) after at least six months of standard anticoagulation therapy as an additional treatment option alongside the already approved rivaroxaban 20 mg once-daily dose.”
If you or a loved one suffered injuries (or worse) as a result of taking Xarelto or another drug in the United States, you should promptly seek the legal advice of a pharmaceutical claim lawyer in your state who may investigate your drug claim for you and represent you in a claim against a pharmaceutical company, if appropriate.
Visit our website or call us toll-free in the United States at 800-295-3959 to be connected with drug claim lawyers in your state who may assist you.
Turn to us when you don’t know where to turn.